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Patient Centered Outcomes Following Endovascular
Intervention for Critical Limb Ischemia
Javier E. Anaya-Ayala, Christopher J. Smolock, Charudatta
S. Bavare, Mitul S. Patel, Hosam F. El-Sayed, Jean Bis-
muth, Eric K. Peden, Alan Lumsden, Mark G. Davies.
Cardiovascular Surgery, Methodist DeBakey Heart & Vas-
cular Center, Houston, TX
Objectives: Over the last decade, there has been a signif-
icant increase in primary endoluminal therapy for critical limb
ischemia (CLI; rest pain and tissue loss) of the lower extremity
(LE) with limited reporting on patient centered outcomes
using the new objective performance goals of the SVS.
Methods: A prospective database of patients undergo-
ing endovascular treatment of the LE for CLI between
2000 and 2011 was queried. Patient centered outcomes of
clinical efficacy (CE; absence of recurrent symptoms, main-
tenance of ambulation and absence of major amputation),
amputation-free survival (AFS; survival without major am-
putation) and freedom from major adverse limb events
(MALE; Above ankle amputation of the index limb or
major re-intervention (new bypass graft, jump/interposi-
tion graft revision) were evaluated.
Results: 728 patients (60% male, age 6814years)
underwent LE interventions for CLI (66% tissue loss). 39%
had both SFA and tibial interventions. 71% had diabetes
mellitus, 64% had hyperlipidemia and 37% had chronic
renal insufficiency. Technical success was 96%. Overall
MACE was 3% and MALE was 22% at 30 days. At 5 years,
CE was 425%, (MeanSEM), AFS 417% and MALE
514%. CE was significantly different in those presenting
with rest pain and tissue loss (Fig).
Conclusions: Endoluminal therapy for CLI is associ-
ated with an early lowMACE but a high MALE. Longer-
term outcomes remain relatively poor with less that a
40% success in patient centered outcomes at 5 years.
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A Novel Mouse Model of Hind Limb Ischemia to Test
Therapeutic Angiogenesis
Robert Brenes2, Caroline C. Jadlowiec1, Mackenzie Bear1,
Peter Hashim1, Clinton D. Protack1, Xin Li1, Wei Lv1,
Michael J. Collins1, Alan Dardik1. 1Interdepartmental Pro-
gram in Vascular Biology and Therapeutics, Yale University
School of Medicine, New Haven, CT; 2Saint Mary’s Hos-
pital, The Stanley J. Dudrick Department of Surgery, Wa-
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Objectives:Clinical trials currently evaluating stem cell
therapy for patients with critical limb ischemia are con-
ducted with different protocols, including use of different
stem cell populations and different injection protocols,
providing little means to compare trials and guide therapy.
Accordingly, we developed a murine model of severe isch-
emia to allow methodical testing of relevant clinical
parameters.
Methods: High femoral artery ligation and total exci-
sion of the superficial femoral artery was performed on
C57BL/6 mice. MNC were isolated from the bone mar-
row of donor mice and injected into the semimembranosus
or gastrocnemius muscle. Vascular and functional out-
comes were measured using invasive Doppler, laser Dopp-
ler perfusion imaging, and the Tarlov and ischemia scores.
Histological analysis included quantification of muscle fiber
area and number as well as capillary density.
Results: Blood flow and functional outcomes were
improved in MNC-treated mice as compared to controls
over a 4-week time course (Flow: P  .0001; Tarlov: P 
.0004; ischemia score: P .0002). MNC-treated mice also
showed greater gastrocnemius fiber area (P  .0053) and
increased capillary density (P  .0004). Dose-response
analysis showed increased angiogenesis and gastrocnemius
fiber area but no changes in macroscopic vascular flow or
functional scores. Mice injected proximally to the ischemic
area had overall similar functional outcomes to mice in-Fig.
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